Open-Label Proof of Concept Study of LTX-315 in Basal Cell Carcinoma
Status:
Not yet recruiting
Trial end date:
2023-02-28
Target enrollment:
Participant gender:
Summary
This is a 3-part, open-label, multicenter, dose-escalation, proof-of-concept study with a
safety run-in designed to assess the safety, tolerability, MTD, and objective antitumor
efficacy of ascending dose strengths of LTX 315 when administered intratumorally to adults
with biopsy proven basal cell carcinoma (BCC).
The study is expected to enroll approximately 66 subjects with a histological diagnosis of
BCC in at least 1 eligible target lesion (confirmed by punch biopsy).
Phase:
Phase 2
Details
Lead Sponsor:
Verrica Pharmaceuticals Inc.
Collaborators:
HeartcoR Solutions Instat Clinical Research Myonex OncoBay Clinical